2018 CANADIAN PHARMACEUTICAL MARKET HIGHLIGHTS



Source: IQVIA. Canadian CompuScript. MAT December 2018, as at February 2019

RETAIL PHARMACIES DISPENSED

699.2

MILLION PRESCRIPTIONS



GENERICS =
71.5% SHARE OF THE MARKET, UP 5.7%

BRAND =
28.5% SHARE OF THE MARKET, DOWN 0.4%



Source: IQVIA. Canadian CompuScript. MAT December 2018, as at January 2019

TOP 10 PRODUCTS

BY TOTAL ETHICAL PRESCRIPTIONS

RANK	PRODUCT	% CHANGE OVER 2017
1	SYNTHROID	+2.9
2	METHADOSE	+20.0
3	APO-ATORVASTATIN	-2.5
4	SANDOZ-BISOPROLOL	+20.4
5	JAMP-VITAMIN D	+21.1
6	SANDOZ-AMLODIPINE	+25.2
7	TEVA-FUROSEMIDE	+4.6
8	SANDOZ METFORMIN FC	-14.4
9	APO-ROSUVASTATIN	+0.4
10	TEVA-TRAZODONE	+46.8

Source: IQVIA. Canadian CompuScript. MAT December 2018

2018 CANADIAN PHARMACEUTICAL MARKET HIGHLIGHTS

COMBINED RETAIL AND HOSPITAL PURCHASES = $28.7 BILLION UP 3.9%

BRAND GROWTH (+6.3%) GENERICS CHANGE (-4.7%)

Source: IQVIA. Canadian Drugstore and Hospital Audit. MAT December 2018 as at February 2019

LEADING THERAPEUTIC CLASSES (USC-2) IN RETAIL AND HOSPITAL PURCHASES, 2018

RANK	THERAPEUTIC CLASS	TOTAL PURCHASES ($ MILLIONS)	GROWTH (%)
1	ANTIARTHRITICS	$2,907	+5.7
2	ONCOLOGY	$2,897	+23.8
3	PSYCHOTHERAPEUTICS	$2,187	-0.6
4	DIABETES THERAPY	$1,893	+10.3
5	ANTIVIRALS	$1,749	+1.3
6	RESPIRATORY THERAPY	$1,515	+7.1
7	CARDIOVASCULARS	$1,451	-13.0
8	IMMUNOLOGIC AGENTS	$1,298	+25.6
9	OPHTHALMICS	$1,277	+12.4
10	NEUROLOGICAL DISORDERS, MISC.	$1,029	-5.9
	TOP 10 TOTAL	**$18,204**	**+6.6**

Source: IQVIA. Canadian Drugstore and Hospital Audit. MAT December 2018

RETAIL PHARMACY CHANNELS

CHAINS & BANNERS:
7,042

FOOD/MASS MERCHANDISERS:
1,575

INDEPENDENTS:
2,075

TOTAL: 10,692



Source: IQVIA. TSA. MAT December 2018

OTC, ALL CHANNEL SALES = $5.467 BILLION, UP 2%

Source: Nielsen/IQVIA National (ex Nfld) all channel sales, 52 weeks ending January 5, 2019